OSM-0205
Prevention of Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Chemotherapy-Induced Cognitive Impairment (CICI)
Key Facts
About Osmol Therapeutics
Osmol Therapeutics is addressing a critical unmet need in oncology supportive care: the prevention of chemotherapy-induced neurotoxicities, CIPN and CICI, for which there are no approved treatments. The company's lead asset, OSM-0205, is a prophylactic intravenous therapy designed to be administered just before chemotherapy to block the initial neuronal damage. By targeting the underlying calcium surge mechanism, Osmol aims to allow patients to receive full, effective chemotherapy doses without dose reductions due to side effects, potentially improving cancer survival rates. The company is currently in the preclinical stage, with a focused pipeline and a clear path toward clinical development.
View full company profile